InvestorsHub Logo
Followers 1
Posts 13
Boards Moderated 0
Alias Born 05/13/2017

Re: None

Sunday, 07/30/2017 6:57:39 PM

Sunday, July 30, 2017 6:57:39 PM

Post# of 335
Is Saniona ( Sanion listed on Nasdaq Stockholm )
a potential Zafgen 2.0?

Pipeline:

Tesomet - Type 2 diabetes - 23 billion USD (Clinical phase 2)
Tesomet PWS - Prader-Willi syndrome - 2 billion USD only in USA (Clinical phase 2)
Tesofensine - Obesity - 250 million USD only in Mexiko (Clinical phase 3) (Tested in 1300 patients.)
NS2359 - Cocaine addiction - 1,8 billion USD only in USA (Clinical phase 2)
GABA-A a2/a3 program - Neuropathic pain - 6 billion USD (Preclinical research)
Boehringer Ingelheim program - Schizofreni - 4,8 billion USD (Preclinical research)
IK - Inflammation,IBD - 5,9 billion USD (Preclinical research)
Nicotinic a6 program - Parkinson - 2,8 billion USD (Preclinical research)
Proximagen program - Neurological disorders - No data (Preclinical research)
Luc Therapeutic program - Ataxi - Rare disease (Preclinical research)

Approximately 40% of the stocks are own by the board and management.

Current market cap 133 million USD.

Alpha Deal analysis:

https://www.biostock.se/wp-content/uploads/2017/07/Saniona_AB_24072017_24.pdf

http://saniona.com/pipeline/

http://saniona.com/investors/ownership-struture/

What do you guys think?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent LRMR News